Invest Ophthalmol Vis Sci:PET可以作为非侵入性的手段来研究玻璃体内注射的药代动力学特征!

2017-06-03 cuiguizhong MedSci原创

西班牙圣地亚哥德孔波斯特拉大学(CIMUS)眼科的González F团队近日在Invest Ophthalmol Vis Sci杂志上发表了他们近期的一项研究工作。文章指出,在研究玻璃体清除随时间的变化过程中,正电子发射断层扫描(PET)可以作为非侵入性的手段来研究玻璃体内注射的药代动力学特征。

西班牙圣地亚哥德孔波斯特拉大学(CIMUS)眼科的González F团队近日在Invest Ophthalmol Vis Sci杂志上发表了他们近期的一项研究工作。文章指出,在研究玻璃体清除随时间的变化过程中,正电子发射断层扫描(PET)可以作为非侵入性的手段来研究玻璃体内注射的药代动力学特征。

González F团队向成年的Sprague Dawley大鼠的玻璃体内注射用18氟(18F)标记的分子,通过使用专用的小动物PET /计算机断层摄影扫描仪来研究其药代动力学特征。研究了他们也设计了不同的实验条件:三个用18F标记的分子(18F-FDG,18F-NaF和18F-Choline),三种不同注射剂量(7,4和2μL),以及是否存在眼部炎症(葡萄膜炎)的情况 。

他们的研究结果表明,放射性标记的分子之间有显着性的药代动力学差异,但在不同注射剂量之间没有显着的药代动力学差异。另外一个有趣的发现是,是否存在葡萄膜炎是玻璃体清除的重要影响因素。在葡萄膜炎存在的情况下,消除药物明显加快。

因此,使用专用PET成像技术可以作为玻璃体内药代动力学特征的研究手段,而这可以为小动物眼科药物开发提供无创的技术手段。这项研究有望推进眼科药物开发的进程!

原文出处:

Fernandez-Ferreiro, A., et al., Preclinical PET Study of Intravitreal Injections. Invest Ophthalmol Vis Sci, 2017. 58(7): p. 2843-2851.

本文系williamhill asia 医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1666657, encodeId=815e166665e75, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Fri Feb 16 05:32:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034663, encodeId=153e2034663e5, content=<a href='/topic/show?id=cf91992e053' target=_blank style='color:#2F92EE;'>#非侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99270, encryptionId=cf91992e053, topicName=非侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Fri Feb 23 23:32:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028750, encodeId=48df2028e5040, content=<a href='/topic/show?id=b1e1269e5c6' target=_blank style='color:#2F92EE;'>#侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26975, encryptionId=b1e1269e5c6, topicName=侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Tue Aug 01 12:32:00 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745747, encodeId=84c51e4574792, content=<a href='/topic/show?id=79ab685899e' target=_blank style='color:#2F92EE;'>#玻璃体内注射#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68589, encryptionId=79ab685899e, topicName=玻璃体内注射)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6da635562893, createdName=cathymary, createdTime=Mon Jan 08 19:32:00 CST 2018, time=2018-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053634, encodeId=bb02205363448, content=<a href='/topic/show?id=e8646858880' target=_blank style='color:#2F92EE;'>#玻璃体内#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68588, encryptionId=e8646858880, topicName=玻璃体内)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Wed Jan 10 05:32:00 CST 2018, time=2018-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726454, encodeId=fcf71e26454f8, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Sep 18 10:32:00 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050711, encodeId=a9e22050e113f, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Aug 23 19:32:00 CST 2017, time=2017-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331059, encodeId=3d35133105907, content=<a href='/topic/show?id=15e2140e438' target=_blank style='color:#2F92EE;'>#PET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14074, encryptionId=15e2140e438, topicName=PET)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5PdY90y5Jib8FnPhCXTR2d9v3K17epNSwB2eb0vmXUldNJl2e72S4unZTAHLAojicdVSialTDFHAxA/132, createdBy=78d82500042, createdName=ms7514935887898259, createdTime=Sun Jun 04 15:32:00 CST 2017, time=2017-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351260, encodeId=b3de135126041, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87289, encryptionId=9ac28e2893e, topicName=药代动力学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jun 04 15:32:00 CST 2017, time=2017-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496204, encodeId=5679149620421, content=<a href='/topic/show?id=bab46858ee3' target=_blank style='color:#2F92EE;'>#玻璃体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68587, encryptionId=bab46858ee3, topicName=玻璃体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47bd9248134, createdName=yykkxiaodou, createdTime=Sun Jun 04 15:32:00 CST 2017, time=2017-06-04, status=1, ipAttribution=)]
    2018-02-16 fengyqf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1666657, encodeId=815e166665e75, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Fri Feb 16 05:32:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034663, encodeId=153e2034663e5, content=<a href='/topic/show?id=cf91992e053' target=_blank style='color:#2F92EE;'>#非侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99270, encryptionId=cf91992e053, topicName=非侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Fri Feb 23 23:32:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028750, encodeId=48df2028e5040, content=<a href='/topic/show?id=b1e1269e5c6' target=_blank style='color:#2F92EE;'>#侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26975, encryptionId=b1e1269e5c6, topicName=侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Tue Aug 01 12:32:00 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745747, encodeId=84c51e4574792, content=<a href='/topic/show?id=79ab685899e' target=_blank style='color:#2F92EE;'>#玻璃体内注射#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68589, encryptionId=79ab685899e, topicName=玻璃体内注射)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6da635562893, createdName=cathymary, createdTime=Mon Jan 08 19:32:00 CST 2018, time=2018-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053634, encodeId=bb02205363448, content=<a href='/topic/show?id=e8646858880' target=_blank style='color:#2F92EE;'>#玻璃体内#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68588, encryptionId=e8646858880, topicName=玻璃体内)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Wed Jan 10 05:32:00 CST 2018, time=2018-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726454, encodeId=fcf71e26454f8, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Sep 18 10:32:00 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050711, encodeId=a9e22050e113f, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Aug 23 19:32:00 CST 2017, time=2017-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331059, encodeId=3d35133105907, content=<a href='/topic/show?id=15e2140e438' target=_blank style='color:#2F92EE;'>#PET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14074, encryptionId=15e2140e438, topicName=PET)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5PdY90y5Jib8FnPhCXTR2d9v3K17epNSwB2eb0vmXUldNJl2e72S4unZTAHLAojicdVSialTDFHAxA/132, createdBy=78d82500042, createdName=ms7514935887898259, createdTime=Sun Jun 04 15:32:00 CST 2017, time=2017-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351260, encodeId=b3de135126041, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87289, encryptionId=9ac28e2893e, topicName=药代动力学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jun 04 15:32:00 CST 2017, time=2017-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496204, encodeId=5679149620421, content=<a href='/topic/show?id=bab46858ee3' target=_blank style='color:#2F92EE;'>#玻璃体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68587, encryptionId=bab46858ee3, topicName=玻璃体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47bd9248134, createdName=yykkxiaodou, createdTime=Sun Jun 04 15:32:00 CST 2017, time=2017-06-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1666657, encodeId=815e166665e75, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Fri Feb 16 05:32:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034663, encodeId=153e2034663e5, content=<a href='/topic/show?id=cf91992e053' target=_blank style='color:#2F92EE;'>#非侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99270, encryptionId=cf91992e053, topicName=非侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Fri Feb 23 23:32:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028750, encodeId=48df2028e5040, content=<a href='/topic/show?id=b1e1269e5c6' target=_blank style='color:#2F92EE;'>#侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26975, encryptionId=b1e1269e5c6, topicName=侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Tue Aug 01 12:32:00 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745747, encodeId=84c51e4574792, content=<a href='/topic/show?id=79ab685899e' target=_blank style='color:#2F92EE;'>#玻璃体内注射#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68589, encryptionId=79ab685899e, topicName=玻璃体内注射)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6da635562893, createdName=cathymary, createdTime=Mon Jan 08 19:32:00 CST 2018, time=2018-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053634, encodeId=bb02205363448, content=<a href='/topic/show?id=e8646858880' target=_blank style='color:#2F92EE;'>#玻璃体内#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68588, encryptionId=e8646858880, topicName=玻璃体内)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Wed Jan 10 05:32:00 CST 2018, time=2018-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726454, encodeId=fcf71e26454f8, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Sep 18 10:32:00 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050711, encodeId=a9e22050e113f, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Aug 23 19:32:00 CST 2017, time=2017-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331059, encodeId=3d35133105907, content=<a href='/topic/show?id=15e2140e438' target=_blank style='color:#2F92EE;'>#PET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14074, encryptionId=15e2140e438, topicName=PET)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5PdY90y5Jib8FnPhCXTR2d9v3K17epNSwB2eb0vmXUldNJl2e72S4unZTAHLAojicdVSialTDFHAxA/132, createdBy=78d82500042, createdName=ms7514935887898259, createdTime=Sun Jun 04 15:32:00 CST 2017, time=2017-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351260, encodeId=b3de135126041, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87289, encryptionId=9ac28e2893e, topicName=药代动力学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jun 04 15:32:00 CST 2017, time=2017-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496204, encodeId=5679149620421, content=<a href='/topic/show?id=bab46858ee3' target=_blank style='color:#2F92EE;'>#玻璃体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68587, encryptionId=bab46858ee3, topicName=玻璃体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47bd9248134, createdName=yykkxiaodou, createdTime=Sun Jun 04 15:32:00 CST 2017, time=2017-06-04, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1666657, encodeId=815e166665e75, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Fri Feb 16 05:32:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034663, encodeId=153e2034663e5, content=<a href='/topic/show?id=cf91992e053' target=_blank style='color:#2F92EE;'>#非侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99270, encryptionId=cf91992e053, topicName=非侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Fri Feb 23 23:32:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028750, encodeId=48df2028e5040, content=<a href='/topic/show?id=b1e1269e5c6' target=_blank style='color:#2F92EE;'>#侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26975, encryptionId=b1e1269e5c6, topicName=侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Tue Aug 01 12:32:00 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745747, encodeId=84c51e4574792, content=<a href='/topic/show?id=79ab685899e' target=_blank style='color:#2F92EE;'>#玻璃体内注射#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68589, encryptionId=79ab685899e, topicName=玻璃体内注射)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6da635562893, createdName=cathymary, createdTime=Mon Jan 08 19:32:00 CST 2018, time=2018-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053634, encodeId=bb02205363448, content=<a href='/topic/show?id=e8646858880' target=_blank style='color:#2F92EE;'>#玻璃体内#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68588, encryptionId=e8646858880, topicName=玻璃体内)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Wed Jan 10 05:32:00 CST 2018, time=2018-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726454, encodeId=fcf71e26454f8, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Sep 18 10:32:00 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050711, encodeId=a9e22050e113f, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Aug 23 19:32:00 CST 2017, time=2017-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331059, encodeId=3d35133105907, content=<a href='/topic/show?id=15e2140e438' target=_blank style='color:#2F92EE;'>#PET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14074, encryptionId=15e2140e438, topicName=PET)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5PdY90y5Jib8FnPhCXTR2d9v3K17epNSwB2eb0vmXUldNJl2e72S4unZTAHLAojicdVSialTDFHAxA/132, createdBy=78d82500042, createdName=ms7514935887898259, createdTime=Sun Jun 04 15:32:00 CST 2017, time=2017-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351260, encodeId=b3de135126041, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87289, encryptionId=9ac28e2893e, topicName=药代动力学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jun 04 15:32:00 CST 2017, time=2017-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496204, encodeId=5679149620421, content=<a href='/topic/show?id=bab46858ee3' target=_blank style='color:#2F92EE;'>#玻璃体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68587, encryptionId=bab46858ee3, topicName=玻璃体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47bd9248134, createdName=yykkxiaodou, createdTime=Sun Jun 04 15:32:00 CST 2017, time=2017-06-04, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1666657, encodeId=815e166665e75, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Fri Feb 16 05:32:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034663, encodeId=153e2034663e5, content=<a href='/topic/show?id=cf91992e053' target=_blank style='color:#2F92EE;'>#非侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99270, encryptionId=cf91992e053, topicName=非侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Fri Feb 23 23:32:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028750, encodeId=48df2028e5040, content=<a href='/topic/show?id=b1e1269e5c6' target=_blank style='color:#2F92EE;'>#侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26975, encryptionId=b1e1269e5c6, topicName=侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Tue Aug 01 12:32:00 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745747, encodeId=84c51e4574792, content=<a href='/topic/show?id=79ab685899e' target=_blank style='color:#2F92EE;'>#玻璃体内注射#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68589, encryptionId=79ab685899e, topicName=玻璃体内注射)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6da635562893, createdName=cathymary, createdTime=Mon Jan 08 19:32:00 CST 2018, time=2018-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053634, encodeId=bb02205363448, content=<a href='/topic/show?id=e8646858880' target=_blank style='color:#2F92EE;'>#玻璃体内#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68588, encryptionId=e8646858880, topicName=玻璃体内)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Wed Jan 10 05:32:00 CST 2018, time=2018-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726454, encodeId=fcf71e26454f8, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Sep 18 10:32:00 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050711, encodeId=a9e22050e113f, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Aug 23 19:32:00 CST 2017, time=2017-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331059, encodeId=3d35133105907, content=<a href='/topic/show?id=15e2140e438' target=_blank style='color:#2F92EE;'>#PET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14074, encryptionId=15e2140e438, topicName=PET)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5PdY90y5Jib8FnPhCXTR2d9v3K17epNSwB2eb0vmXUldNJl2e72S4unZTAHLAojicdVSialTDFHAxA/132, createdBy=78d82500042, createdName=ms7514935887898259, createdTime=Sun Jun 04 15:32:00 CST 2017, time=2017-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351260, encodeId=b3de135126041, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87289, encryptionId=9ac28e2893e, topicName=药代动力学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jun 04 15:32:00 CST 2017, time=2017-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496204, encodeId=5679149620421, content=<a href='/topic/show?id=bab46858ee3' target=_blank style='color:#2F92EE;'>#玻璃体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68587, encryptionId=bab46858ee3, topicName=玻璃体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47bd9248134, createdName=yykkxiaodou, createdTime=Sun Jun 04 15:32:00 CST 2017, time=2017-06-04, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1666657, encodeId=815e166665e75, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Fri Feb 16 05:32:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034663, encodeId=153e2034663e5, content=<a href='/topic/show?id=cf91992e053' target=_blank style='color:#2F92EE;'>#非侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99270, encryptionId=cf91992e053, topicName=非侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Fri Feb 23 23:32:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028750, encodeId=48df2028e5040, content=<a href='/topic/show?id=b1e1269e5c6' target=_blank style='color:#2F92EE;'>#侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26975, encryptionId=b1e1269e5c6, topicName=侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Tue Aug 01 12:32:00 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745747, encodeId=84c51e4574792, content=<a href='/topic/show?id=79ab685899e' target=_blank style='color:#2F92EE;'>#玻璃体内注射#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68589, encryptionId=79ab685899e, topicName=玻璃体内注射)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6da635562893, createdName=cathymary, createdTime=Mon Jan 08 19:32:00 CST 2018, time=2018-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053634, encodeId=bb02205363448, content=<a href='/topic/show?id=e8646858880' target=_blank style='color:#2F92EE;'>#玻璃体内#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68588, encryptionId=e8646858880, topicName=玻璃体内)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Wed Jan 10 05:32:00 CST 2018, time=2018-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726454, encodeId=fcf71e26454f8, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Sep 18 10:32:00 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050711, encodeId=a9e22050e113f, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Aug 23 19:32:00 CST 2017, time=2017-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331059, encodeId=3d35133105907, content=<a href='/topic/show?id=15e2140e438' target=_blank style='color:#2F92EE;'>#PET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14074, encryptionId=15e2140e438, topicName=PET)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5PdY90y5Jib8FnPhCXTR2d9v3K17epNSwB2eb0vmXUldNJl2e72S4unZTAHLAojicdVSialTDFHAxA/132, createdBy=78d82500042, createdName=ms7514935887898259, createdTime=Sun Jun 04 15:32:00 CST 2017, time=2017-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351260, encodeId=b3de135126041, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87289, encryptionId=9ac28e2893e, topicName=药代动力学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jun 04 15:32:00 CST 2017, time=2017-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496204, encodeId=5679149620421, content=<a href='/topic/show?id=bab46858ee3' target=_blank style='color:#2F92EE;'>#玻璃体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68587, encryptionId=bab46858ee3, topicName=玻璃体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47bd9248134, createdName=yykkxiaodou, createdTime=Sun Jun 04 15:32:00 CST 2017, time=2017-06-04, status=1, ipAttribution=)]
    2017-09-18 feather89
  7. [GetPortalCommentsPageByObjectIdResponse(id=1666657, encodeId=815e166665e75, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Fri Feb 16 05:32:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034663, encodeId=153e2034663e5, content=<a href='/topic/show?id=cf91992e053' target=_blank style='color:#2F92EE;'>#非侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99270, encryptionId=cf91992e053, topicName=非侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Fri Feb 23 23:32:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028750, encodeId=48df2028e5040, content=<a href='/topic/show?id=b1e1269e5c6' target=_blank style='color:#2F92EE;'>#侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26975, encryptionId=b1e1269e5c6, topicName=侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Tue Aug 01 12:32:00 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745747, encodeId=84c51e4574792, content=<a href='/topic/show?id=79ab685899e' target=_blank style='color:#2F92EE;'>#玻璃体内注射#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68589, encryptionId=79ab685899e, topicName=玻璃体内注射)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6da635562893, createdName=cathymary, createdTime=Mon Jan 08 19:32:00 CST 2018, time=2018-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053634, encodeId=bb02205363448, content=<a href='/topic/show?id=e8646858880' target=_blank style='color:#2F92EE;'>#玻璃体内#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68588, encryptionId=e8646858880, topicName=玻璃体内)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Wed Jan 10 05:32:00 CST 2018, time=2018-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726454, encodeId=fcf71e26454f8, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Sep 18 10:32:00 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050711, encodeId=a9e22050e113f, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Aug 23 19:32:00 CST 2017, time=2017-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331059, encodeId=3d35133105907, content=<a href='/topic/show?id=15e2140e438' target=_blank style='color:#2F92EE;'>#PET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14074, encryptionId=15e2140e438, topicName=PET)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5PdY90y5Jib8FnPhCXTR2d9v3K17epNSwB2eb0vmXUldNJl2e72S4unZTAHLAojicdVSialTDFHAxA/132, createdBy=78d82500042, createdName=ms7514935887898259, createdTime=Sun Jun 04 15:32:00 CST 2017, time=2017-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351260, encodeId=b3de135126041, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87289, encryptionId=9ac28e2893e, topicName=药代动力学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jun 04 15:32:00 CST 2017, time=2017-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496204, encodeId=5679149620421, content=<a href='/topic/show?id=bab46858ee3' target=_blank style='color:#2F92EE;'>#玻璃体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68587, encryptionId=bab46858ee3, topicName=玻璃体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47bd9248134, createdName=yykkxiaodou, createdTime=Sun Jun 04 15:32:00 CST 2017, time=2017-06-04, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1666657, encodeId=815e166665e75, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Fri Feb 16 05:32:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034663, encodeId=153e2034663e5, content=<a href='/topic/show?id=cf91992e053' target=_blank style='color:#2F92EE;'>#非侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99270, encryptionId=cf91992e053, topicName=非侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Fri Feb 23 23:32:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028750, encodeId=48df2028e5040, content=<a href='/topic/show?id=b1e1269e5c6' target=_blank style='color:#2F92EE;'>#侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26975, encryptionId=b1e1269e5c6, topicName=侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Tue Aug 01 12:32:00 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745747, encodeId=84c51e4574792, content=<a href='/topic/show?id=79ab685899e' target=_blank style='color:#2F92EE;'>#玻璃体内注射#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68589, encryptionId=79ab685899e, topicName=玻璃体内注射)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6da635562893, createdName=cathymary, createdTime=Mon Jan 08 19:32:00 CST 2018, time=2018-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053634, encodeId=bb02205363448, content=<a href='/topic/show?id=e8646858880' target=_blank style='color:#2F92EE;'>#玻璃体内#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68588, encryptionId=e8646858880, topicName=玻璃体内)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Wed Jan 10 05:32:00 CST 2018, time=2018-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726454, encodeId=fcf71e26454f8, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Sep 18 10:32:00 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050711, encodeId=a9e22050e113f, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Aug 23 19:32:00 CST 2017, time=2017-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331059, encodeId=3d35133105907, content=<a href='/topic/show?id=15e2140e438' target=_blank style='color:#2F92EE;'>#PET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14074, encryptionId=15e2140e438, topicName=PET)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5PdY90y5Jib8FnPhCXTR2d9v3K17epNSwB2eb0vmXUldNJl2e72S4unZTAHLAojicdVSialTDFHAxA/132, createdBy=78d82500042, createdName=ms7514935887898259, createdTime=Sun Jun 04 15:32:00 CST 2017, time=2017-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351260, encodeId=b3de135126041, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87289, encryptionId=9ac28e2893e, topicName=药代动力学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jun 04 15:32:00 CST 2017, time=2017-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496204, encodeId=5679149620421, content=<a href='/topic/show?id=bab46858ee3' target=_blank style='color:#2F92EE;'>#玻璃体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68587, encryptionId=bab46858ee3, topicName=玻璃体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47bd9248134, createdName=yykkxiaodou, createdTime=Sun Jun 04 15:32:00 CST 2017, time=2017-06-04, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1666657, encodeId=815e166665e75, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Fri Feb 16 05:32:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034663, encodeId=153e2034663e5, content=<a href='/topic/show?id=cf91992e053' target=_blank style='color:#2F92EE;'>#非侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99270, encryptionId=cf91992e053, topicName=非侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Fri Feb 23 23:32:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028750, encodeId=48df2028e5040, content=<a href='/topic/show?id=b1e1269e5c6' target=_blank style='color:#2F92EE;'>#侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26975, encryptionId=b1e1269e5c6, topicName=侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Tue Aug 01 12:32:00 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745747, encodeId=84c51e4574792, content=<a href='/topic/show?id=79ab685899e' target=_blank style='color:#2F92EE;'>#玻璃体内注射#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68589, encryptionId=79ab685899e, topicName=玻璃体内注射)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6da635562893, createdName=cathymary, createdTime=Mon Jan 08 19:32:00 CST 2018, time=2018-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053634, encodeId=bb02205363448, content=<a href='/topic/show?id=e8646858880' target=_blank style='color:#2F92EE;'>#玻璃体内#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68588, encryptionId=e8646858880, topicName=玻璃体内)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Wed Jan 10 05:32:00 CST 2018, time=2018-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726454, encodeId=fcf71e26454f8, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Sep 18 10:32:00 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050711, encodeId=a9e22050e113f, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Aug 23 19:32:00 CST 2017, time=2017-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331059, encodeId=3d35133105907, content=<a href='/topic/show?id=15e2140e438' target=_blank style='color:#2F92EE;'>#PET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14074, encryptionId=15e2140e438, topicName=PET)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5PdY90y5Jib8FnPhCXTR2d9v3K17epNSwB2eb0vmXUldNJl2e72S4unZTAHLAojicdVSialTDFHAxA/132, createdBy=78d82500042, createdName=ms7514935887898259, createdTime=Sun Jun 04 15:32:00 CST 2017, time=2017-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351260, encodeId=b3de135126041, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87289, encryptionId=9ac28e2893e, topicName=药代动力学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jun 04 15:32:00 CST 2017, time=2017-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496204, encodeId=5679149620421, content=<a href='/topic/show?id=bab46858ee3' target=_blank style='color:#2F92EE;'>#玻璃体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68587, encryptionId=bab46858ee3, topicName=玻璃体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47bd9248134, createdName=yykkxiaodou, createdTime=Sun Jun 04 15:32:00 CST 2017, time=2017-06-04, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1666657, encodeId=815e166665e75, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Fri Feb 16 05:32:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034663, encodeId=153e2034663e5, content=<a href='/topic/show?id=cf91992e053' target=_blank style='color:#2F92EE;'>#非侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99270, encryptionId=cf91992e053, topicName=非侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Fri Feb 23 23:32:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028750, encodeId=48df2028e5040, content=<a href='/topic/show?id=b1e1269e5c6' target=_blank style='color:#2F92EE;'>#侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26975, encryptionId=b1e1269e5c6, topicName=侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Tue Aug 01 12:32:00 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745747, encodeId=84c51e4574792, content=<a href='/topic/show?id=79ab685899e' target=_blank style='color:#2F92EE;'>#玻璃体内注射#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68589, encryptionId=79ab685899e, topicName=玻璃体内注射)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6da635562893, createdName=cathymary, createdTime=Mon Jan 08 19:32:00 CST 2018, time=2018-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053634, encodeId=bb02205363448, content=<a href='/topic/show?id=e8646858880' target=_blank style='color:#2F92EE;'>#玻璃体内#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68588, encryptionId=e8646858880, topicName=玻璃体内)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Wed Jan 10 05:32:00 CST 2018, time=2018-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726454, encodeId=fcf71e26454f8, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Sep 18 10:32:00 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050711, encodeId=a9e22050e113f, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Aug 23 19:32:00 CST 2017, time=2017-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331059, encodeId=3d35133105907, content=<a href='/topic/show?id=15e2140e438' target=_blank style='color:#2F92EE;'>#PET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14074, encryptionId=15e2140e438, topicName=PET)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5PdY90y5Jib8FnPhCXTR2d9v3K17epNSwB2eb0vmXUldNJl2e72S4unZTAHLAojicdVSialTDFHAxA/132, createdBy=78d82500042, createdName=ms7514935887898259, createdTime=Sun Jun 04 15:32:00 CST 2017, time=2017-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351260, encodeId=b3de135126041, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87289, encryptionId=9ac28e2893e, topicName=药代动力学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jun 04 15:32:00 CST 2017, time=2017-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496204, encodeId=5679149620421, content=<a href='/topic/show?id=bab46858ee3' target=_blank style='color:#2F92EE;'>#玻璃体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68587, encryptionId=bab46858ee3, topicName=玻璃体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47bd9248134, createdName=yykkxiaodou, createdTime=Sun Jun 04 15:32:00 CST 2017, time=2017-06-04, status=1, ipAttribution=)]

相关威廉亚洲官网

全球“机器人眼科医生”中山眼科中心“看门诊”

AI(人工智能)机器人为你诊断眼病,你信得过吗?5月4日,记者从中山大学中山眼科中心了解到,该院研发了我国首个眼科人工智能诊断决策系统,只需要将先天性白内障患者眼睛的照片上传至云平台,通过AI机器人的深度分析和诊断,几分钟就可以出具诊断、风险评估和治疗方案。目前该AI平台已临床验证了超过300名患者。有关该成果的论文已经在国际一流医学杂志《自然》子刊上作为封面文章发表。中山眼科中心还开辟了全球首个

山东省眼科医院与省红会开展“复明项目工程” 诊疗费免除

5月26日,山东省角膜捐献及白内障复明工程培训班暨济南市红十字会、山东省红十字眼库角膜捐献志愿服务培训班在山东省眼科医院14楼学术报告厅胜利召开。

Ophthalmologica:糖尿病黄斑水肿患者的眼房水中可溶性血管内皮生长因子受体(sVEGFR)和炎症因子的水平显著高于非糖尿病人!

日本东京医科大学医学中心眼科系的Shimura M实验室在最新一期的Ophthalmologica上发表了他们近期的一项工作。他们测量了35例(37只眼)接受抗血管内皮生长因子(VEGF)治疗的糖尿病性黄斑水肿(DME)患者眼房水中可溶性血管内皮生长因子受体(sVEGFR)和炎性因子的水平。

患者称正做眼科手术机器停转,南京鼓楼医院眼科:发生在术前

4月11日,南京市鼓楼医院眼科“正在进行一起矫正近视的飞秒激光手术,仪器突然停止运转”。近日,南京市民路先生向记者诉说了自己的这一遭遇。他说,医生在表示歉意的同时称,仪器一时半会修不好,要求其回家等待通知。回家后,路先生发现自己出现眼部充血、浮肿的现象,并感到阵阵酸痛。时隔一天后的4月12日,路先生到医院复查后,被告知眼部充血的现象属于正常。院方提出,要么继续手术,要么全额退还医疗费。对此,路先生

Ophthalmology:在增生性玻璃体视网膜病变研究慢性释放地塞米松的作用--前瞻性、随机的临床对照试验

英国伦敦Moorfields眼科医院的Charteris DG教授实验室近期在Ophthalmology发表了他们的一项杰出工作。他们提出一个假设,地塞米松作为外源植入物,缓慢释放地塞米松可以提高患有增生性玻璃体视网膜病变(PVR)患者在玻璃体视网膜手术后的愈后效果。为了测试这一假设,他们设计了一个为期2年的,单中心,前瞻性,参与者和外科医生双盲随机对照临床试验(EudraCT No. 2011-

Ophthalmic Res: MicroRNA-200b在增生性糖尿病视网膜病变患者玻璃体中的表达显着增高!

埃及亚历山大大学医学部眼科系的Moftah RF实验室在最新的一期Ophthalmic Res杂志上发表了他们团队一项重要的工作,揭示了miRNA-200b和VEGF在PDR患者的玻璃体中的表达情况。